293 related articles for article (PubMed ID: 15003452)
1. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Xu RX; Rocque WJ; Lambert MH; Vanderwall DE; Luther MA; Nolte RT
J Mol Biol; 2004 Mar; 337(2):355-65. PubMed ID: 15003452
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
3. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
4. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity.
Herman SB; Juilfs DM; Fauman EB; Juneau P; Menetski JP
Mol Pharmacol; 2000 May; 57(5):991-9. PubMed ID: 10779384
[TBL] [Abstract][Full Text] [Related]
5. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
6. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
Scapin G; Patel SB; Chung C; Varnerin JP; Edmondson SD; Mastracchio A; Parmee ER; Singh SB; Becker JW; Van der Ploeg LH; Tota MR
Biochemistry; 2004 May; 43(20):6091-100. PubMed ID: 15147193
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of phosphodiesterase 4D and inhibitor complex(1).
Lee ME; Markowitz J; Lee JO; Lee H
FEBS Lett; 2002 Oct; 530(1-3):53-8. PubMed ID: 12387865
[TBL] [Abstract][Full Text] [Related]
9. Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding.
Rocque WJ; Holmes WD; Patel IR; Dougherty RW; Ittoop O; Overton L; Hoffman CR; Wisely GB; Willard DH; Luther MA
Protein Expr Purif; 1997 Mar; 9(2):191-202. PubMed ID: 9056484
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors.
Liu S; Laliberté F; Bobechko B; Bartlett A; Lario P; Gorseth E; Van Hamme J; Gresser MJ; Huang Z
Biochemistry; 2001 Aug; 40(34):10179-86. PubMed ID: 11513595
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity.
Huai Q; Wang H; Sun Y; Kim HY; Liu Y; Ke H
Structure; 2003 Jul; 11(7):865-73. PubMed ID: 12842049
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the relationship between protein-protein interaction and catalytic activity of a heme-regulated phosphodiesterase from Escherichia coli (Ec DOS) by protein microarray.
Sasakura Y; Kanda K; Yoshimura-Suzuki T; Matsui T; Fukuzono S; Shimizu T
Biochemistry; 2005 Jul; 44(28):9598-605. PubMed ID: 16008345
[TBL] [Abstract][Full Text] [Related]
13. Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis.
Cheung PP; Yu L; Zhang H; Colman RW
Arch Biochem Biophys; 1998 Dec; 360(1):99-104. PubMed ID: 9826434
[TBL] [Abstract][Full Text] [Related]
14. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
[TBL] [Abstract][Full Text] [Related]
15. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis.
Huai Q; Colicelli J; Ke H
Biochemistry; 2003 Nov; 42(45):13220-6. PubMed ID: 14609333
[TBL] [Abstract][Full Text] [Related]
16. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
Zhu B; Kelly J; Vemavarapu L; Thompson WJ; Strada SJ
Biochem Pharmacol; 2004 Aug; 68(3):479-91. PubMed ID: 15242814
[TBL] [Abstract][Full Text] [Related]
17. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate.
Tian G; Rocque WJ; Wiseman JS; Thompson IZ; Holmes WD; Domanico PL; Stafford JA; Feldman PL; Luther MA
Biochemistry; 1998 May; 37(19):6894-904. PubMed ID: 9578576
[TBL] [Abstract][Full Text] [Related]
19. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
[No Abstract] [Full Text] [Related]
20. TcPDE4, a novel membrane-associated cAMP-specific phosphodiesterase from Trypanosoma cruzi.
Alonso GD; Schoijet AC; Torres HN; Flawiá MM
Mol Biochem Parasitol; 2006 Jan; 145(1):40-9. PubMed ID: 16225937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
